CDK12 deficiency and the immune microenvironment in prostate cancer

Tamara L. Lotan; Emmanuel S. Antonarakis

doi:10.1158/1078-0432.CCR-20-3877

CDK12 deficiency and the immune microenvironment in prostate cancer

Tamara L. Lotan, Emmanuel S. Antonarakis

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4^þFOXP3 T cells were increased compared with CDK12-proficient controls.

Original language	English (US)
Pages (from-to)	380-382
Number of pages	3
Journal	Clinical Cancer Research
Volume	27
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-20-3877
State	Published - Jan 15 2021

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-20-3877

Cite this

@article{1c479637a57c421bbc2ed4f3e5e9e264,

title = "CDK12 deficiency and the immune microenvironment in prostate cancer",

abstract = "CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4{\th}FOXP3 T cells were increased compared with CDK12-proficient controls.",

author = "Lotan, {Tamara L.} and Antonarakis, {Emmanuel S.}",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2021",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-20-3877",

language = "English (US)",

volume = "27",

pages = "380--382",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

TY - JOUR

T1 - CDK12 deficiency and the immune microenvironment in prostate cancer

AU - Lotan, Tamara L.

AU - Antonarakis, Emmanuel S.

PY - 2021/1/15

Y1 - 2021/1/15

N2 - CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4þFOXP3 T cells were increased compared with CDK12-proficient controls.

AB - CDK12 inactivation in prostate cancer is associated with tandem genomic duplications that may generate fusion-associated neoantigens and elicit immune responses amenable to checkpoint blockade. In the first study to comprehensively characterize the T-cell immune microenvironment of CDK12-deficient prostate cancers, subsets of immunosuppressive CD4þFOXP3 T cells were increased compared with CDK12-proficient controls.

UR - http://www.scopus.com/inward/record.url?scp=85100352375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100352375&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-20-3877

DO - 10.1158/1078-0432.CCR-20-3877

M3 - Article

C2 - 33199495

AN - SCOPUS:85100352375

SN - 1078-0432

VL - 27

SP - 380

EP - 382

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 2

ER -

CDK12 deficiency and the immune microenvironment in prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this